Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 5/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | SOD3 | P08294 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL254649 | 0.94 | GNAO1 (0.38) | MEN1KMT2AGNAO1GNAI3GNAI1 | |
| SCHEMBL3254587 | 0.92 | GNAO1 (0.40) | GNAO1GNAI3GNAI1SOD3 | |
| SCHEMBL3044885 | 0.88 | — | — | |
| SCHEMBL6961881 | 0.80 | KEAP1 (0.32) | — | |
| SCHEMBL3533333 | 0.80 | — | — | |
| SCHEMBL447925 | 0.79 | — | — | |
| SCHEMBL11969012 | 0.76 | OPRD1 (0.30) | — | |
| SCHEMBL361683 | 0.75 | — | — | |
| SCHEMBL1476931 | 0.74 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL11599897 | 0.71 | POLB (0.52) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110128373-B | Piperazinyl tin complex, preparation method thereof, thin film and solar cell | 鸿翌科技有限公司 | 2023-03-24 | — | — | CN | claimed |
| US-4279912-A | ANTIALLERGENS, BRONCHODILATORS | ROUSSEL UCLAF (FR) | 1981-07-21 | — | — | US | claimed |
| US-4091115-A | ANTIDEPRESSANTS | ROUSSEL UCLAF (FR) | 1978-05-23 | — | — | US | claimed |
| EP-3311813-B1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2019-08-07 | — | — | EP | disclosed |
| US-10053467-B2 | Therapeutic isoxazole compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-08-21 | — | — | US | disclosed |
| EP-3311813-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | Dart Neuroscience (Cayman) Ltd (KY) | 2018-04-25 | — | — | EP | disclosed |
| EP-2182809-B1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2018-01-17 | — | — | EP | disclosed |
| US-20170204111-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE LLC | 2017-07-20 | — | — | US | disclosed |
| US-9650349-B2 | Therapeutic isoxazole compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-05-16 | — | — | US | disclosed |
| US-20150336941-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE LLC | 2015-11-26 | — | — | US | disclosed |
| US-9029397-B2 | Therapeutic isoxazole compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-05-12 | — | — | US | disclosed |
| EP-2182809-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | Helicon Therapeutics, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009029632-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20090062252-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-4576964-A | ANALGESICS, ANTIEMETICS | PFIZER INC. (US) | 1986-03-18 | — | — | US | disclosed |
| US-4476131-A | ANTIEMETICS, ANALGESICS | PFIZER INC. (US) | 1984-10-09 | — | — | US | disclosed |
| US-4279912-A | ANTIALLERGENS, BRONCHODILATORS | ROUSSEL UCLAF (FR) | 1981-07-21 | — | — | US | disclosed |
| US-4154852-A | ANTIDEPRESSANTS | ROUSSEL UCLAF (FR) | 1979-05-15 | — | — | US | disclosed |
| US-4145419-A | ANTIALLERGENS, BRONCHODILATORS | ROUSSEL UCLAF (FR) | 1979-03-20 | — | — | US | disclosed |
| US-4091115-A | ANTIDEPRESSANTS | ROUSSEL UCLAF (FR) | 1978-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053467-B2 | Therapeutic isoxazole compounds | MAOB, MAOA, XDH | MEN1 3625/4885KMT2A 1192/4885GNAO1 682/4885 |
| US-20150336941-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | MAOB, MAOA, XDH | MEN1 3625/4885KMT2A 1192/4885GNAO1 682/4885 |
| US-20170204111-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | MAOB, MAOA, XDH | MEN1 3625/4885KMT2A 1192/4885GNAO1 682/4885 |
| US-20090062252-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | MAOB, MAOA, XDH | MEN1 3625/4885KMT2A 1192/4885GNAO1 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.